AstraZeneca’s investigational COVID drug meets primary goals in late-stage study
By Thomson ReutersMay 16, 2024 | 2:21 AM
(Reuters) – AstraZeneca said on Thursday its investigational drug, sipavibart, met primary goals in preventing COVID-19 in immunocompromised patients in a late-stage trial.
(Reporting by Eva Mathews in Bengaluru; Editing by Sherry Jacob-Phillips)
Comments